A Phase I, Dose-Escalating, Safety Study of an Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PL-MLP, PROMITIL) in Cancer Patients With Solid Tumors
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; PL MLP (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Lipomedix Pharmaceuticals
- 23 Jan 2020 According to the Lipomedix Pharmaceuticals media release, this study analyzed 53 patients with advanced, treatment-refractory CRC.
- 23 Jan 2020 Results presented in a Lipomedix Pharmaceuticals Media Release.
- 23 Jan 2020 According to the Lipomedix Pharmaceuticals media release, data were published in in the research journal Investigational New Drugs.